Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab

This narrative review seeks to summarize chemotherapeutic regimens commonly used for patients with newly diagnosed Philadelphia (Ph) chromosome-negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in the frontline setting and to describe the latest clinical research using the bispecific...

Descripción completa

Detalles Bibliográficos
Autores: Jabbour, E.J.|||0000-0003-4465-6119, Kantarjian, Hagop M.|||0000-0002-1908-3307, Goekbuget, N., Shah, B.D., Chiaretti, S., Park, J.H.|||0000-0002-2903-5130, Rijneveld, A.W., Gore, L., Fleming, S., Logan, A.C., Ribera, Jose-Maria|||0000-0003-1042-6024, Menne, T.F., Mezzi, K., Zaman, F., Velasco, K., Boissel, Nicolas|||0000-0003-2091-7927
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:310583
Acceso en línea:https://ddd.uab.cat/record/310583
https://dx.doi.org/urn:doi:10.1038/s41408-024-01179-4
Access Level:acceso abierto
Palabra clave:Antibodies, Bispecific
Humans
Philadelphia Chromosome
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Descripción
Sumario:This narrative review seeks to summarize chemotherapeutic regimens commonly used for patients with newly diagnosed Philadelphia (Ph) chromosome-negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in the frontline setting and to describe the latest clinical research using the bispecific T-cell-engaging immunotherapy blinatumomab in the first-line treatment setting. Current standard-of-care chemotherapeutic backbones for newly diagnosed Ph-negative BCP-ALL are based on the same overarching treatment principle: to reduce disease burden to undetectable levels and maintain lasting remission. The adult treatment landscape has progressively evolved following the adoption of pediatric-inspired regimens. However, these intense regimens are not tolerated by all, and high-risk patients still have inferior outcomes. Therefore, designing more effective and less toxic strategies remains key to further improving efficacy and safety outcomes. Overall, the treatment landscape is evolving in the frontline, and integration of blinatumomab into different standard frontline regimens may improve overall outcomes with a favorable safety profile.

Similares en LA Referencia